Market capitalization | $3.50m |
Enterprise Value | $1.07m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | 4.20 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-11.76m |
Free Cash Flow (TTM) Free Cash Flow | $-9.80m |
Cash position | $1.76m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Portage Biotech Inc:
1 Analyst has issued a forecast Portage Biotech Inc:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.04 -0.04 |
33%
33%
|
|
EBITDA | -12 -12 |
41%
41%
|
EBIT (Operating Income) EBIT | -12 -12 |
41%
41%
|
Net Profit | -67 -67 |
40%
40%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Portage Biotech, Inc. is a biotechnology company, which enables research and development to produce clinical programs and maximize potential returns. Its portfolio includes subsidiary companies, whose products or technologies have established scientific rationales, including intratumorals, nanoparticles, liposomes, aptamers, cell penetrating peptides, and virus-like particles. The firm provides funding, strategic business and clinical counsel, and shared services to treat different types of cancers. The company was founded by Gregory H. Bailey in 1973 and is headquartered in Road Town, British Virgin Islands.
Head office | Virgin Islands, British |
CEO | Ian Walters |
Employees | 7 |
Founded | 1973 |
Website | www.portagebiotech.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.